09/01/2026
đ°Editorial Recommendations - January 2026
This month, IBD-ENC presents five carefully curated articles from high-impact journals, offering key insights into the evolving management of inflammatory bowel disease (IBD).
1) Evidence supports early use of vedolizumab in Crohnâs disease, showing improved remission and safety outcomes
2) A novel oral bispecific antibody (SOR102) demonstrates promising early efficacy in ulcerative colitis
3) New multinational Asian data enhance understanding of PSC-IBD prevalence and outcomes
4) Long-term registry data reveal a declining risk of colorectal cancer after low-grade dysplasia in IBD
5) A meta-analysis questions the continued role of 5-ASA after escalation to advanced therapies
Together, these studies provide a concise snapshot of clinically relevant advances shaping contemporary IBD practice.
đ Explore more at: www.ibdenc.org